

RESEARCH ARTICLE

Open Access

The association between microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional study

Aamer Sandoo^{1,2*}, Douglas Carroll², George S Metsios¹, George D Kitas^{1,3} and Jet JCS Veldhuijzen van Zanten^{1,2}

Abstract

Introduction: Patients with rheumatoid arthritis (RA) are at an increased risk for cardiovascular disease (CVD). One of the earliest manifestations of CVD is endothelial dysfunction (ED). ED can occur in both the microcirculation and the macrocirculation, and these manifestations might be relatively independent of each other. Little is known about the association between endothelial function in the microcirculation and the macrocirculation in RA. The objectives of the present study were to examine the relationship between microvascular and macrovascular endothelial function in patients with RA.

Methods: Ninety-nine RA patients (72 females, mean age (\pm SD) 56 ± 12 years), underwent assessments of endothelial-dependent (acetylcholine) and endothelial-independent (sodium nitroprusside) microvascular vasodilatory function (laser Doppler imaging with iontophoresis), as well as endothelial-dependent (flow-mediated dilation) and endothelial-independent (glyceryl trinitrate-mediated dilation) macrovascular vasodilatory function. Vasodilatory function was calculated as the percentage increase after each stimulus was applied relative to baseline values.

Results: Pearson correlations showed that microvascular endothelial-dependent function was not associated with macrovascular endothelial-dependent function (r (90 patients) = 0.10, P = 0.34). Similarly, microvascular endothelial-independent function was not related to macrovascular endothelial-independent function (r (89 patients) = 0.00, P = 0.99).

Conclusions: Microvascular and macrovascular endothelial function were independent of each other in patients with RA, suggesting differential regulation of endothelial function in these two vascular beds. Assessments of both vascular beds may provide more meaningful clinical information on vascular risk in RA, but this hypothesis needs to be confirmed in long-term prospective studies.

Introduction

The endothelium is the innermost lining of the vasculature and is responsible for maintaining vascular homeostasis via the balanced production of a number of vasoactive factors [1]. One such factor is nitric oxide (NO), which plays an important role in vasodilation and in inhibiting atherosclerotic processes such as thrombosis and leukocyte activation in the vessel wall [2-5]. Damage to the endothelium can reduce NO activity, causing endothelial dysfunction (ED), which is an early indicator of cardiovascular disease

(CVD) [6]. The extent of ED can be characterised by assessing endothelial function in different vascular beds of the peripheral circulation [7]. These assessments are reflective of coronary endothelial function [8-11] and have been shown to be good predictors of long-term cardiovascular events in individuals with atherosclerosis [12-15] and peripheral vascular disease [16], as well as in healthy older participants [17].

Endothelial cells can differ in structure and phenotype, depending on the vessel type [18]. Heterogeneous responses to *in vitro* stimulation are displayed in different vascular beds and even in different sections of the same vascular bed [19-21]. This suggests that ED may occur differentially in different vascular beds [21]. Studies that

* Correspondence: aamer.sandoo@dgoh.nhs.uk

¹Department of Rheumatology, Dudley Group of Hospitals NHS Trust, Russells Hall Hospital, Pensnett Road, Dudley, DY1 2HQ, West Midlands, UK
Full list of author information is available at the end of the article

have assessed associations between peripheral microvascular and macrovascular endothelial-dependent function in healthy individuals have reported mixed findings, with some reporting an association between microvascular and macrovascular endothelial-dependent function [22,23] and others reporting no association [24-26].

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease of the joints [27]. RA patients are also at an increased risk for CVD [28], with ED believed to be a contributor to some of this excess CVD risk [29]. RA has a similar CVD risk burden and vascular profile to diabetes [30], a condition in which microvascular disease may contribute to macrovascular disease [31]. There is also some preliminary evidence that coronary microvascular disease may be apparent before macrovascular disease in RA [32]. This highlights the importance of assessing endothelial function in multiple vascular beds.

To our knowledge, only two studies have simultaneously assessed microvascular and macrovascular endothelial function in RA; one study reported no association between the two vascular beds [33], while the other study did find an association [34]. In the former study, microvascular endothelial function was measured using laser Doppler flowmetry, which assesses endothelial function at a single point only and does not account for spatial heterogeneity of skin blood flow in the way that newer techniques such as laser Doppler imaging (LDI) do [35]. A limitation of the second study is that manual methods were used to detect and mark out the vessel diameter during flow-mediated dilation (FMD). This method is less accurate than automated wall tracking software, which detects and calculates arterial diameter in real time and greatly reduces the variability found in the measurements [36,37]. Such limitations suggest that the association between microvascular and macrovascular endothelial function requires further investigation using newer and more accurate assessments of endothelial function. Accordingly, the aim of the present study was to examine the relationship between microvascular and macrovascular endothelium-dependent function in RA using LDI and automated measurements of vascular diameter changes to reactive hyperaemia.

Material and methods

Patients

Ninety-nine consecutive rheumatoid arthritis (RA) patients were recruited from the rheumatology outpatient clinics of the Dudley Group of Hospitals NHS Trust, UK. All patients met the retrospective application of the 1987 revised RA criteria of the American Rheumatism Association [38]. Patients were excluded if they had previously confirmed acute coronary syndrome or established CVD as indicated in their medical records and/or upon questioning during the initial consultation.

The study received local Research Ethics Committee approval, and all participants gave their written informed consent according to the Declaration of Helsinki.

Protocol

Patients reported to a temperature-controlled vascular laboratory (22°C) after a 12-hour overnight fast. For ethical reasons, patients were not asked to refrain from taking RA disease-related or vasoactive medications. All patients underwent a detailed clinical examination, and demographic information was collected from all the participants by questionnaire. The disease activity score in 28 joints [39] was also calculated. Following this step, the participants underwent assessments of microvascular endothelial function using LDI with iontophoresis and assessment of macrovascular endothelial function using FMD and glyceryl trinitrate-mediated dilation (GTN).

Microvascular endothelial function

Endothelial function of the microvasculature was assessed noninvasively using LDI (moorLDI2 SIM; Moor Instruments Ltd, Devon, UK) with iontophoresis of 1% acetylcholine (ACh; endothelium-dependent) and 1% sodium nitroprusside (SNP; endothelium-independent) (Sigma Chemical Co., Montvale, NJ, USA) in 0.5 mL of saline by a single observer (AS). The technique was performed according to previously established guidelines [35] and was described in detail previously [40]. Briefly, after a baseline scan, ten scans were recorded during iontophoresis of the vasoactive agents using a 30 μ A current, followed by two scans during recovery. This technique has intraobserver coefficients of variation (CVs) of 6.5% and 5.9% for ACh and SNP, respectively, in our laboratory.

Macrovascular endothelial function

Assessment of macrovascular endothelial-dependent function was performed using FMD with high-resolution ultrasonography of the brachial artery (ACUSON Antares ultrasound system; Siemens PLC, Camberley, UK) according to previously established guidelines [41]. Following ten minutes of rest, endothelium-independent responses were examined by administration of a 500- μ g sublingual glyceryl trinitrate tablet (Alpharma, Barnstaple, UK) while the brachial artery was imaged continuously for five minutes. The intraobserver CVs were 10.7% for FMD and 11.8% for GTN assessments, respectively. For all vascular tests, endothelial function was expressed as the percentage increase in perfusion or diameter from baseline, and all analysis was carried out offline by AS, who was blinded to the identity of the patient.

Statistical analysis

Statistical analysis was performed using SPSS version 16 software (SPSS Inc, Chicago, IL, USA). Variables were tested for normality by using the Kolmogorov-Smirnov test. Log transformation was performed for positively skewed variables as appropriate. Values are expressed as medians (25th to 75th percentiles) or percentages as appropriate. Pearson's correlations were used to assess the relationships between microvascular and macrovascular endothelium-dependent function.

Results

The patient characteristics are presented in Table 1. The majority of patients were female and had moderate disease activity levels. The percentage increase in blood flow in response to ACh was 311 ± 234 , and for SNP it was 306 ± 199 . For macrovascular endothelial function, the percentage increase in diameter (FMD) after reactive hyperaemia was 9 ± 6 , and the percentage increase in diameter after GTN was 23 ± 9 . Microvascular and macrovascular endothelial function for RA patients were similar to a healthy control group (data not reported).

As shown in Table 2, microvascular endothelium-dependent function was not associated with macrovascular endothelium-dependent function. This was also the case with regard to associations between endothelium-independent function in these two vascular beds.

Discussion

In the present study, we found that in RA patients, microvascular and macrovascular endothelial function are not associated with each other. To our knowledge, only two other studies have examined associations between small- and large-vessel endothelial function in RA patients. One study of 65 RA patients used laser Doppler flowmetry to assess microvascular blood flow and reported findings similar to those of the current study [33], whereas another study of 66 RA patients

reported that microvascular and macrovascular endothelium-dependent function were only moderately associated with each other [34].

Arosio and colleagues [33] examined both microvascular and macrovascular endothelial function by eliciting reactive hyperaemia. Even though both assessments were dependent on shear stress, microvascular and macrovascular endothelial function were not associated with each other [33], which could be due to a difference in exposure to shear stress between the resistance and conduit vessels [42]. Given that the magnitude of shear stress is directly linked to NO release [43], it is possible that differences in shear stress profiles resulted in the lack of association between these two assessments in the study by Arosio and colleagues [33]. Therefore, it is possible that microvascular and macrovascular endothelial function may differ even when a similar stimulus is used.

Foster and colleagues [34] used the same assessments as we used in the present study [34], but the iontophoresis protocol used to administer the vasoactive agents differed between studies in terms of relative administration of the iontophoresis agents (simultaneously in the current study versus consecutively in the previous study), as did the iontophoresis current delivery (30 μ A vs. 100 μ A, respectively). Higher currents can lead to vasodilation from other endothelium-dependent factors, such as bradykinin and substance P [35]. Importantly, artefactual vasodilation from high currents is amplified when water is used as the drug vehicle [44], as in the Foster and colleagues study, but is eliminated when 0.5% sodium chloride is used [44], as in the present study. Thus, differences in protocol make comparing the findings of both studies difficult.

In the present study, differences in NO stimulation between the assessments could have contributed to the independence of the microvessels and macrovessels through differential effects on endothelial cell receptors. Whereas SNP, FMD and GTN predominantly evoke maximum NO release [8,43], NO inhibition reduces only 30% to 40% of the microvascular vasodilatory response induced by ACh [45], suggesting that other factors, such as endothelium-derived hyperpolarising factor, may also contribute to vasodilation in the resistance vessels [46]. In addition, application of pharmacologic (ACh and SNP) [47] and physiologic (shear stress) [48] stimuli activate different endothelial receptors [49], and consequently there may be differences in the vasodilatory response between the two assessments.

In the current work, participants were not asked to withhold their antirheumatic drug treatment or vasoactive medications prior to the vascular assessments, as examining patients while they maintain their normal medication regime may provide a better reflection of the

Table 1 General and disease-related characteristics for the RA patients^a

Characteristics	RA patient data
General characteristics	
Age, years	57 (47 to 65)
Females, %	73%
Body mass index	29 (25 to 34)
Disease-related characteristics	
Disease duration, years	8 (3 to 16)
Rheumatoid factor-positive, %	78%
DAS28 score	3.6 (2.5 to 4.6)
C-reactive protein level, mg/L	5 (2.9 to 13.5)
Erythrocyte sedimentation rate, mm/hour	17 (8.8 to 28.3)

^aDAS28 = disease activity score in 28 joints; RA = rheumatoid arthritis. Results are expressed as medians (25th to 75th percentiles).

Table 2 Correlations between the microvasculature and macrovasculature^a

Measurement	Endothelial-dependent (FMD)	Endothelial-independent (GTN)
Endothelial-dependent (ACh)	$r(90) = 0.10, P = 0.34$	-
Endothelial-independent (SNP)	-	$r(89) = -0.00, P = 0.99$

^aACh = acetylcholine; SNP = sodium nitroprusside; FMD = flow-mediated dilation; GTN = glyceryl trinitrate-mediated dilation.

patient's arterial condition in an everyday setting. However, additional analyses were conducted to explore the influence of vasoactive medication on the association between microvascular and macrovascular function. Excluding patients receiving vasoactive medication ($n = 46$) did not change the findings (data not reported). Another potential limitation of this study is the sample size. However, the effect size of the correlations in the current data is small [50]. This means that, with a power of 0.80 and α set at 0.05, the required sample size to detect a significant association would be 783 participants [50]. Thus, this suggests that the null findings presented in the current study are due to effect size rather than to sample size.

As stated above, assessments of endothelial function have been reported to be good predictors of long-term cardiovascular events in individuals with CVD [12-16] and in healthy older participants [17]. However, in RA, to our knowledge, no studies have examined whether poor endothelial function relates to long-term adverse CV outcomes. Only one study with a relatively small sample size examined the prognostic value of carotid intima media thickness (CIMT), which is an indicator of vascular morphology rather than function [51]. That study showed that patients who experienced a cardiac event during a five-year follow-up period also had greater CIMT at baseline compared to patients without a cardiac event [51]. Therefore, to understand whether and how vascular function is predictive of cardiovascular events, detailed longitudinal assessments are necessary and should include assessment of both the microvasculature and the macrovasculature.

Conclusions

In summary, the present study has shown that microvascular and macrovascular endothelial function were not associated with each other in patients with RA, suggesting that these assessments cannot be used interchangeably in this population. Assessments of both vascular beds may provide more meaningful clinical information on vascular risk in RA, but this needs to be confirmed in long-term prospective studies.

Abbreviations

ACh: acetylcholine; CIMT: carotid intima media thickness; CVD: cardiovascular disease; CV: coefficient of variation; DAS28: disease activity score in 28 joints; ED: endothelial dysfunction; FMD: flow-mediated dilation; GTN: glyceryl

trinitrate-mediated dilation; LDI: laser Doppler imaging; NO: nitric oxide; RA: rheumatoid arthritis; VIA: vascular imaging analysis.

Acknowledgements

The authors thank Dr George Balanos for his help and assistance with the flow-mediated dilation assessment. AS was supported by a PhD studentship of the University of Birmingham and by the Department of Rheumatology, Dudley Group of Hospitals NHS Foundation Trust, Arthritis Research Campaign infrastructure support grant 17682.

Author details

¹Department of Rheumatology, Dudley Group of Hospitals NHS Trust, Russells Hall Hospital, Pensnett Road, Dudley, DY1 2HQ, West Midlands, UK. ²School of Sport and Exercise Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. ³Arthritis Research UK Epidemiology Unit, University of Manchester, Oxford Road, Manchester, M13 9PL, UK.

Authors' contributions

AS participated in the design of the study, recruited patients, performed the vascular assessments, conducted data analysis and drafted the manuscript. DC, GK and JWZ participated in the design of the study and helped with data analysis and drafting the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 22 December 2010 Revised: 27 May 2011

Accepted: 21 June 2011 Published: 21 June 2011

References

- Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, Stern DM: **Endothelial cells in physiology and in the pathophysiology of vascular disorders.** *Blood* 1998, **91**:3527-3561.
- Kubes P, Suzuki M, Granger DN: **Nitric oxide: an endogenous modulator of leukocyte adhesion.** *Proc Natl Acad Sci USA* 1991, **88**:4651-4655.
- Nong Z, Hoylaerts M, Van Pelt N, Collen D, Janssens S: **Nitric oxide inhalation inhibits platelet aggregation and platelet-mediated pulmonary thrombosis in rats.** *Circ Res* 1997, **81**:865-869.
- Gidday JM, Park TS, Shah AR, Gonzales ER: **Modulation of basal and postischemic leukocyte-endothelial adherence by nitric oxide.** *Stroke* 1998, **29**:1423-1430.
- Ahluwalia A, Foster P, Scotland RS, McLean PG, Mathur A, Perretti M, Moncada S, Hobbs AJ: **Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment.** *Proc Natl Acad Sci USA* 2004, **101**:1386-1391.
- Lerman A, Zeiher AM: **Endothelial function: cardiac events.** *Circulation* 2005, **111**:363-368.
- Alam TA, Seifalian AM, Baker D: **A review of methods currently used for assessment of *in vivo* endothelial function.** *Eur J Vasc Endovasc Surg* 2005, **29**:269-276.
- Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thüille C, Lüscher TF: **Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries *in vivo*.** *Circulation* 1995, **91**:1314-1319.
- Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrangé D, Lieberman EH, Ganz P, Creager MA, Yeung AC: **Close relation of endothelial function in the human coronary and peripheral circulations.** *J Am Coll Cardiol* 1995, **26**:1235-1241.
- Takeba B, Hamabe A, Satomura K, Akima T, Uehata A, Ohsuzu F, Ishihara M, Kurita A: **Close relationship between the vasodilator response to acetylcholine in the brachial and coronary artery in suspected coronary artery disease.** *Int J Cardiol* 2005, **105**:58-66.

11. Khan F, Patterson D, Belch JJ, Hirata K, Lang CC: **Relationship between peripheral and coronary function using laser Doppler imaging and transthoracic echocardiography.** *Clin Sci (Lond)* 2008, **115**:295-300.
12. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, Vita JA: **Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease.** *J Am Coll Cardiol* 2003, **41**:1769-1775.
13. Karatzis EN, Ikonomidou I, Vamvakou GD, Papaioannou TG, Protogerou AD, Andreadou I, Voidonikola PT, Karatzi KN, Papamichael CM, Lekakis JP: **Long-term prognostic role of flow-mediated dilatation of the brachial artery after acute coronary syndromes without ST elevation.** *Am J Cardiol* 2006, **98**:1424-1428.
14. Schächinger V, Britten MB, Zeiher AM: **Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease.** *Circulation* 2000, **101**:1899-1906.
15. Corrado E, Camarda P, Coppola G, Muratori I, Ciaramitaro G, Farinella M, Novo G, Rotolo A, Andolina G, Cospite V, Evola S, Assennato P, Hoffmann E, Novo S: **Prognostic role of endothelial dysfunction and carotid intima-media thickness in patients undergoing coronary stent implantation.** *Int Angiol* 2009, **28**:12-19.
16. Brevetti G, Silvestro A, Schiano V, Chiariello M: **Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index.** *Circulation* 2003, **108**:2093-2098.
17. Yeboah J, Burke GL, Crouse JR, Herrington DM: **Relationship between brachial flow-mediated dilation and carotid intima-media thickness in an elderly cohort: the Cardiovascular Health Study.** *Atherosclerosis* 2008, **197**:840-845.
18. Ghitescu L, Robert M: **Diversity in unity: the biochemical composition of the endothelial cell surface varies between the vascular beds.** *Microsc Res Tech* 2002, **57**:381-389.
19. Ferrer M, Encabo A, Conde MV, Marín J, Balfagón G: **Heterogeneity of endothelium-dependent mechanisms in different rabbit arteries.** *J Vasc Res* 1995, **32**:339-346.
20. Thorin E, Shtatos MA, Shreeve SM, Walters CL, Bevan JA: **Human vascular endothelium heterogeneity: a comparative study of cerebral and peripheral cultured vascular endothelial cells.** *Stroke* 1997, **28**:375-381.
21. Hill CE, Phillips JK, Sandow SL: **Heterogeneous control of blood flow amongst different vascular beds.** *Med Res Rev* 2001, **21**:1-60.
22. Hansell J, Henareh L, Agewall S, Norman M: **Non-invasive assessment of endothelial function: relation between vasodilatory responses in skin microcirculation and brachial artery.** *Clin Physiol Funct Imaging* 2004, **24**:317-322.
23. Irace C, Ceravolo R, Notarangelo L, Crescenzo A, Ventura G, Tamburrini O, Perticone F, Gnasso A: **Comparison of endothelial function evaluated by strain gauge plethysmography and brachial artery ultrasound.** *Atherosclerosis* 2001, **158**:53-59.
24. Eskurza I, Seals DR, DeSouza CA, Tanaka H: **Pharmacologic versus flow-mediated assessments of peripheral vascular endothelial vasodilatory function in humans.** *Am J Cardiol* 2001, **88**:1067-1069.
25. Lind L, Hall J, Larsson A, Annuk M, Fellström B, Lithell H: **Evaluation of endothelium-dependent vasodilation in the human peripheral circulation.** *Clin Physiol* 2000, **20**:440-448.
26. Green DJ, Walsh JH, Maiorana A, Burke V, Taylor RR, O'Driscoll JG: **Comparison of resistance and conduit vessel nitric oxide-mediated vascular function in vivo: effects of exercise training.** *J Appl Physiol* 2004, **97**:749-755.
27. Maini RN: **Rheumatoid arthritis: a paradigm of inflammatory disease of the musculoskeletal system.** *Acta Orthop Scand Suppl* 1998, **281**:6-13.
28. Kitas GD, Erb N: **Tackling ischaemic heart disease in rheumatoid arthritis.** *Rheumatology (Oxford)* 2003, **42**:607-613.
29. Sattar N, McInnes IB: **Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions.** *Curr Opin Rheumatol* 2005, **17**:286-292.
30. Stamatelopoulou KS, Kitas GD, Papamichael CM, Chrysoshoou E, Kyrkou K, Georgiopoulos G, Protogerou A, Panoulas VF, Sandoo A, Tentolouris N, Mavrikakis M, Sfikakis PP: **Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study.** *Arterioscler Thromb Vasc Biol* 2009, **29**:1702-1708.
31. Krentz AJ, Clough G, Byrne CD: **Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications.** *Diabetes Obes Metab* 2007, **9**:781-791.
32. Banks M, Flint J, Bacon PA, Kitas GD: **Rheumatoid arthritis is an independent risk factor for ischaemic heart disease [abstract].** *Arthritis Rheum* 2000, **43(Suppl 9)**:S385.
33. Arosio E, De Marchi S, Rigoni A, Prior M, Delva P, Lechi A: **Forearm haemodynamics, arterial stiffness and microcirculatory reactivity in rheumatoid arthritis.** *J Hypertens* 2007, **25**:1273-1278.
34. Foster W, Carruthers D, Lip GY, Blann AD: **Inflammation and microvascular and macrovascular endothelial dysfunction in rheumatoid arthritis: effect of treatment.** *J Rheumatol* 2010, **37**:711-716.
35. Turner J, Belch JJ, Khan F: **Current concepts in assessment of microvascular endothelial function using laser Doppler imaging and iontophoresis.** *Trends Cardiovasc Med* 2008, **18**:109-116.
36. Sonka M, Liang W, Lauer RM: **Automated analysis of brachial ultrasound image sequences: early detection of cardiovascular disease via surrogates of endothelial function.** *IEEE Trans Med Imaging* 2002, **21**:1271-1279.
37. Sidhu JS, Newey VR, Nassiri DK, Kaski JC: **A rapid and reproducible on line automated technique to determine endothelial function.** *Heart* 2002, **88**:289-292.
38. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: **The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.** *Arthritis Rheum* 1988, **31**:315-324.
39. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL: **Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.** *Arthritis Rheum* 1995, **38**:44-48.
40. Sandoo A, van Zanten JJ, Metsios GS, Carroll D, Kitas GD: **The endothelium and its role in regulating vascular tone.** *Open Cardiovasc Med J* 2010, **4**:302-312.
41. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R, International Brachial Artery Reactivity Task Force: **Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force.** *J Am Coll Cardiol* 2002, **39**:257-265.
42. Pries AR, Secomb TW, Gaetgens P: **Design principles of vascular beds.** *Circ Res* 1995, **77**:1017-1023.
43. Moncada S, Palmer RM, Higgs EA: **Nitric oxide: physiology, pathophysiology, and pharmacology.** *Pharmacol Rev* 1991, **43**:109-142.
44. Ferrell WR, Ramsay JE, Brooks N, Lockhart JC, Dickson S, McNeece GM, Greer IA, Sattar N: **Elimination of electrically induced iontophoretic artefacts: implications for non-invasive assessment of peripheral microvascular function.** *J Vasc Res* 2002, **39**:447-455.
45. Newby DE, Boon NA, Webb DJ: **Comparison of forearm vasodilatation to substance P and acetylcholine: contribution of nitric oxide.** *Clin Sci (Lond)* 1997, **92**:133-138.
46. Feletou M, Vanhoutte PM: **Endothelium-derived hyperpolarizing factor: where are we now?** *Arterioscler Thromb Vasc Biol* 2006, **26**:1215-1225.
47. Felder CC: **Muscarinic acetylcholine receptors: signal transduction through multiple effectors.** *FASEB J* 1995, **9**:619-625.
48. Cooke JP, Rossitch E Jr, Andon NA, Loscalzo J, Dzau VJ: **Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator.** *J Clin Invest* 1991, **88**:1663-1671.
49. Traub O, Berk BC: **Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force.** *Arterioscler Thromb Vasc Biol* 1998, **18**:677-685.
50. Cohen J: **A power primer.** *Psychol Bull* 1992, **112**:155-159.
51. Gonzalez-Juanatey C, Llorca J, Martin J, Gonzalez-Gay MA: **Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis.** *Semin Arthritis Rheum* 2009, **38**:366-371.

doi:10.1186/ar3374

Cite this article as: Sandoo et al.: The association between microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional study. *Arthritis Research & Therapy* 2011 **13**:R99.